New Weight-Loss drug tested in kidney patients
NCT ID NCT07559240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study will test a single dose of the experimental drug HDM1005 in 30 overweight or obese adults, some with moderate or severe kidney disease and some with healthy kidneys. The goal is to see how kidney function affects the drug's levels in the body and to check for safety issues. This is a Phase 1 trial, meaning it's one of the first steps in human testing, so it's focused on safety and drug processing rather than weight loss itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HDM1005 injection
What this could lead to
If successful, this study could help determine safe dosing of HDM1005 for people with kidney problems, potentially leading to a weight management option for this group.
What could go wrong
This is a very early Phase 1 study with only 30 participants, so results may not apply broadly. The drug may not work as expected or could have side effects, especially in those with kidney impairment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
Beijing, 100191, China
Contact
Contact